AU2020256283B2 - Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof - Google Patents

Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

Info

Publication number
AU2020256283B2
AU2020256283B2 AU2020256283A AU2020256283A AU2020256283B2 AU 2020256283 B2 AU2020256283 B2 AU 2020256283B2 AU 2020256283 A AU2020256283 A AU 2020256283A AU 2020256283 A AU2020256283 A AU 2020256283A AU 2020256283 B2 AU2020256283 B2 AU 2020256283B2
Authority
AU
Australia
Prior art keywords
pcv3
composition
protein
dose
orf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020256283A
Other languages
English (en)
Other versions
AU2020256283A1 (en
AU2020256283A8 (en
Inventor
Dave Michael Anstrom
Bailey Arruda
Luis Gabriel Gimenez-Lirola
Luis Alejandro HERNANDEZ
Arun Iyer
Abby PATTERSON
Pablo E. Pineyro Pineiro
Eric M. Vaughn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Iowa State University Research Foundation Inc ISURF
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Iowa State University Research Foundation Inc ISURF filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AU2020256283A1 publication Critical patent/AU2020256283A1/en
Assigned to IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Boehringer lngelheim Vetmedica GMBH reassignment IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Request for Assignment Assignors: Boehringer Ingelheim Animal Health USA Inc., IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Publication of AU2020256283A8 publication Critical patent/AU2020256283A8/en
Application granted granted Critical
Publication of AU2020256283B2 publication Critical patent/AU2020256283B2/en
Priority to AU2025267386A priority Critical patent/AU2025267386A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020256283A 2019-04-04 2020-04-06 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof Active AU2020256283B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025267386A AU2025267386A1 (en) 2019-04-04 2025-11-12 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829400P 2019-04-04 2019-04-04
US62/829,400 2019-04-04
PCT/US2020/026930 WO2020206452A1 (en) 2019-04-04 2020-04-06 Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025267386A Division AU2025267386A1 (en) 2019-04-04 2025-11-12 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

Publications (3)

Publication Number Publication Date
AU2020256283A1 AU2020256283A1 (en) 2021-11-18
AU2020256283A8 AU2020256283A8 (en) 2024-01-11
AU2020256283B2 true AU2020256283B2 (en) 2025-08-14

Family

ID=70680577

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020256283A Active AU2020256283B2 (en) 2019-04-04 2020-04-06 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
AU2025267386A Pending AU2025267386A1 (en) 2019-04-04 2025-11-12 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025267386A Pending AU2025267386A1 (en) 2019-04-04 2025-11-12 Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof

Country Status (13)

Country Link
US (4) US11701419B2 (https=)
EP (1) EP3953370A1 (https=)
JP (1) JP7762565B2 (https=)
KR (1) KR20220004967A (https=)
CN (1) CN114222579A (https=)
AU (2) AU2020256283B2 (https=)
BR (1) BR112021019859A2 (https=)
CA (1) CA3136141A1 (https=)
CL (1) CL2021002582A1 (https=)
MX (2) MX2021012051A (https=)
PH (1) PH12021552477A1 (https=)
WO (1) WO2020206452A1 (https=)
ZA (1) ZA202107428B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066772A1 (en) 2015-10-16 2017-04-20 Kansas State University Research Foundation Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
BR112021019859A2 (pt) * 2019-04-04 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
CN115028688B (zh) * 2022-04-28 2024-04-16 山东信得科技股份有限公司 PCV3 Cap蛋白抗原肽、抗体及PCV3检测用免疫组化试剂盒
CN115960250B (zh) * 2022-08-06 2025-09-09 武汉科前生物股份有限公司 一种重组猪圆环病毒3型三聚体蛋白及其制备方法与应用
CN119019544B (zh) * 2024-08-09 2025-10-17 浙江理工大学 一种猪圆环病毒3型抗原检测试剂条及制备方法和应用
CN119307516A (zh) * 2024-11-15 2025-01-14 扬州大学 一种重组猪圆环病毒3型cap基因片段及其在双抗原夹心elisa抗体检测中的应用
CN119780429B (zh) * 2024-12-27 2025-12-26 华派生物技术(集团)股份有限公司 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066772A1 (en) * 2015-10-16 2017-04-20 Kansas State University Research Foundation Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
CN108823231A (zh) * 2018-07-09 2018-11-16 荣俊 一种猪圆环病毒3型基因工程亚单位疫苗及其制备方法
WO2018223668A1 (zh) * 2017-06-09 2018-12-13 普莱柯生物工程股份有限公司 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3479708A (en) 1968-05-15 1969-11-25 Edson P Foster Felting needle
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
AU7966987A (en) 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69522984T2 (de) 1994-04-11 2002-04-25 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
EP0732340B1 (en) 1995-03-14 2004-06-09 Akzo Nobel N.V. Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
PT2460817T (pt) 2004-12-30 2017-07-03 Boehringer Ingelheim Vetmedica Inc Composições imunogénicas de pcv2 e métodos de produção de tais composições
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
DK3766518T3 (da) 2005-12-29 2026-04-13 Boehringer Ingelheim Animal Health Usa Inc Immunogen pcv2-sammensætning til mindskelse af kliniske symptomer hos grise
PT2094872T (pt) 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP2215231A4 (en) 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CN103002911B (zh) * 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
HRP20151031T1 (hr) 2011-02-17 2015-11-06 Boehringer Ingelheim Vetmedica Gmbh Novi europski soj prrsv
CN104288760A (zh) 2013-07-18 2015-01-21 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
MX381132B (es) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra parvovirus porcino.
CN108619503A (zh) 2017-03-24 2018-10-09 华南农业大学 一种猪圆环病毒基因工程亚单位疫苗及其制备方法与应用
CN108785667B (zh) 2017-04-28 2021-04-27 普莱柯生物工程股份有限公司 一种猪圆环病毒3型免疫原性组合物、制备方法和应用
CN109125719B (zh) 2017-06-19 2022-06-14 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型、猪圆环病毒2型抗原的免疫原性组合物及其应用
CN109125720B (zh) * 2017-06-19 2021-11-09 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型抗原的免疫原性组合物及其应用
CN108159409A (zh) * 2017-12-25 2018-06-15 南京大爻网络科技有限公司 一种猪圆环病毒3型Cap蛋白疫苗及其制备方法和应用
CN108359677A (zh) * 2018-02-01 2018-08-03 福建农林大学 提高猪圆环病毒2型和3型Cap蛋白串联表达效率的方法
JP7822127B2 (ja) * 2018-06-11 2026-03-02 セヴァ サンテ アニマレ ブタサーコウイルスに対するワクチン接種
CN109053896B (zh) * 2018-07-03 2021-08-17 青岛明勤生物科技有限公司 一种猪圆环病毒二价基因工程疫苗
CN109207522B (zh) 2018-08-12 2022-05-27 扬州大学 表达猪圆环病毒3型截短Cap蛋白重组杆状病毒及其构建方法与引物
CN109207441B (zh) 2018-08-12 2022-05-27 扬州大学 重组杆状病毒表达猪圆环病毒3型Cap蛋白及其构建方法与引物
CN109550045B (zh) * 2018-12-26 2023-01-31 哈药集团生物疫苗有限公司 猪圆环病毒3型、猪细小病毒和猪流感三联灭活疫苗及其制备方法
CN109852622B (zh) 2019-01-18 2022-05-27 南京农业大学 一种可溶性PCV3Cap蛋白及其编码基因和应用
BR112021019859A2 (pt) * 2019-04-04 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066772A1 (en) * 2015-10-16 2017-04-20 Kansas State University Research Foundation Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
WO2018223668A1 (zh) * 2017-06-09 2018-12-13 普莱柯生物工程股份有限公司 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
CN108823231A (zh) * 2018-07-09 2018-11-16 荣俊 一种猪圆环病毒3型基因工程亚单位疫苗及其制备方法

Also Published As

Publication number Publication date
AU2025267386A1 (en) 2026-01-29
US11701419B2 (en) 2023-07-18
US20230302113A1 (en) 2023-09-28
US20210128712A1 (en) 2021-05-06
AU2020256283A1 (en) 2021-11-18
US20240226264A1 (en) 2024-07-11
US11896659B2 (en) 2024-02-13
MX2021012051A (es) 2022-01-18
CL2021002582A1 (es) 2022-07-22
US20260069672A1 (en) 2026-03-12
CA3136141A1 (en) 2020-10-08
EP3953370A1 (en) 2022-02-16
MX2025004075A (es) 2025-06-02
BR112021019859A2 (pt) 2022-02-15
JP2022527627A (ja) 2022-06-02
CN114222579A (zh) 2022-03-22
AU2020256283A8 (en) 2024-01-11
ZA202107428B (en) 2023-12-20
PH12021552477A1 (en) 2022-07-18
JP7762565B2 (ja) 2025-10-30
US12433942B2 (en) 2025-10-07
WO2020206452A1 (en) 2020-10-08
KR20220004967A (ko) 2022-01-12

Similar Documents

Publication Publication Date Title
AU2020256283B2 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
US12331080B2 (en) Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
CA3042573A1 (en) Vaccine against porcine parvovirus
CN110387355B (zh) 表达猪圆环病毒Cap蛋白基因的重组猪伪狂犬病病毒株、疫苗及其制备方法和应用
EP3277315A2 (en) Pcv2 orf2 carrier platform
JPH03504963A (ja) 仮性狂犬病感染に対する組換えサブユニットワクチンの調製
CN113355287A (zh) 一种猪圆环病毒2型及3型二价疫苗及其制备方法
KR20230013017A (ko) 아프리카 돼지 열병 바이러스 감염에 대한 백신
CN110256539B (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
US20150202282A1 (en) Pcv2 orf2 virus like particle with foreign amino acid insertion
CN114058524A (zh) 一种法氏囊亚病毒颗粒疫苗及其制备方法
RU2813989C2 (ru) Вакцины против свиного цирковируса 3 типа (pcv3), их производство и применение
RU2803427C1 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
CN111712575B (zh) 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
BR122024015306B1 (pt) Vetor compreendendo uma sequência de ácido nucleico que codifica uma proteína do circovírus suíno do tipo 3, célula hospedeira e composição compreendendo o mesmo

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

Free format text: FORMER APPLICANT(S): BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

Owner name: BOEHRINGER LNGELHEIM VETMEDICA GMBH

Free format text: FORMER APPLICANT(S): BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

TH Corrigenda

Free format text: IN VOL 35 , NO 46 , PAGE(S) 9018 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BOEHRINGER LNGELHEIM VETMEDICA GMBH; IIOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC., APPLICATION NO. 2020256283, UNDER INID (71) CORRECT THE APPLICANT NAME TO BOEHRINGER LNGELHEIM VETMEDICA GMBH; IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

FGA Letters patent sealed or granted (standard patent)